Feds Loosen Grip on Cannabis
Retrieved on:
Tuesday, January 18, 2022
Emerald, Light, Drug Enforcement Administration, PH, PTSD, Research, Technology, News, PAR, Opioid, Drug, Sleep apnea, Biological response modifier, Good manufacturing practice, CBD, Cannabis, Growth, Humidity, Soil, CEO, Chronic pain, DEA, Automation, Veteran, Temperature, Interview, Wireless, HVAC, Health, API, Communication, THC, Government, Law enforcement, Anxiety, United States Department of Veterans Affairs, Edward Hines Jr. Veterans Administration Hospital, CO2, Depression, CGMP, Multimedia, Horticulture, Food, Federation, FDA, REP, Food and Drug Administration, Active ingredient, LED, University, Pharmaceutical industry, Dietary supplement
REP is the first-of-its-kind cannabis pharmaceutical company in the United States to receive these highly coveted licenses.
Key Points:
- REP is the first-of-its-kind cannabis pharmaceutical company in the United States to receive these highly coveted licenses.
- This latest move by the DEA is a clear message that the federal government is loosening its grip on marijuana specifically grown for research purposes.
- It has been a long and hard battle for entrepreneurs in the cannabis industry to win approval from the DEA, but now it has finally happened.
- "We are excited and very happy to receive these DEA licenses for cannabis research," said Mark Crozier, Founder and CEO of Royal Emerald Pharmaceuticals.